MedTrace Logo

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

NCT06932705 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-04-17

No results posted yet for this study

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.

Conditions

  • Mixed Dyslipidemia

Interventions

DRUG

PA-111

PA-111 1Tab., Per Oral

DRUG

PA-111A

PA-111A 1Capsule., Per Oral

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932705 on ClinicalTrials.gov